Projects per year
Personal profile
Biography
Stephen Opat is the director of Clinical Haematology at Monash Health, a dynamic academic research organization that integrates the best evidence–base into routine patient care. It provides haematology care to a population of approximately 1.3 million, making it one of the largest services in Australia. Key leadership areas in clinical care and research include: Lymphoid cancer, chronic myeloid disorders, thromboembolic disease, haemoglobinopathy and transfusion medicine. It is an active member of a number of research organisations including the Monash Health Translation Precinct (MHTP), the Centre for Cancer Research (CCR) at the Hudson Institute of Medical Research, and the Australasian Leukaemia and Lymphoma Group. His particular interests include the diagnosis and management of lymphoma and chronic lymphocytic leukaemia, cancer genomics, disorders of iron metabolism, Gaucher disease and novel therapies. He is the principal investigator in over 30 clinical trials mainly in lymphoid cancer and founder of the Australasian Lymphoma and Related Diseases Registry. He has a strong interest in medical education, particularly in developing countries, and has lectured widely throughout the Asia-Pacific. He is extremely active in the Haematology Society of Australia and New Zealand where he currently serves as President.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Lymphoma
- Genomics
- Chronic Lymphocytic Leukaemia
- Cancer Immunology
- Cancer Cell Biology
Collaborations and top research areas from the last five years
-
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/ Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Opat, S. (Primary Chief Investigator (PCI))
13/08/25 → 12/08/30
Project: Research
-
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Investigator’s Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)
Opat, S. (Primary Chief Investigator (PCI))
16/09/24 → 15/09/29
Project: Research
-
A Phase 3, Multicenter, Randomized, Open-Label Trial of Epcoritamab plus Lenalidomide compared to Rituximab plus Gemcitabine and Oxaliplatin in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Opat, S. (Primary Chief Investigator (PCI)) & Gregory, G. (Chief Investigator (CI))
20/08/24 → 19/08/29
Project: Research
-
A Phase 1/1b Open-Label Dose-Escalation Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies
Opat, S. (Primary Chief Investigator (PCI))
1/08/24 → 31/07/29
Project: Research
-
A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma
Opat, S. (Primary Chief Investigator (PCI))
13/03/24 → 12/03/29
Project: Research
-
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach
Tedjaseputra, A., Tey, A., Nalpantidis, A., Grigoriadis, G., Fleming, S., Vilcassim, S., Fedele, P. L., Low, M. S. Y., Yeh, P., Gilbertson, M., Bennett, A., Gregory, G. P., Oh, D., Gairns, D., Kaplan, Z., Chunilal, S. D., Brown, S., Opat, S., Chua, C. C. & Shortt, J., May 2025, In: Internal Medicine Journal. 55, 5, p. 749-759 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Too soon to reject immunoglobulin replacement in CLL
Opat, S. & Salvaris, R., 28 Oct 2025, In: Blood Advances. 9, 20, p. 5380-5381 2 p.Research output: Contribution to journal › Letter › Other › peer-review
Open Access -
Zanubrutinib in Bing Neel syndrome: efficacy and tolerability: LYMPHOMA
Becking, A. M. L., van de Mortel, J. P. M., Tomkins, O., Flinsenberg, T. W. H., Japzon, N., Kersten, M. J., Khwaja, J., Kuipers, S., Levenga, H., McKeague, S., Opat, S., Salvaris, R. T., Seif, S., Thomas, S. K., Vrancken, A. F. J. E., D’Sa, S., Minnema, M. C. & Vos, J. M. I., May 2025, In: Leukemia. 39, 5, p. 1260–1264 5 p.Research output: Contribution to journal › Letter › Other › peer-review
Open Access7 Citations (Scopus) -
A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma Risk
Odutola, M. K., van Leeuwen, M. T., Bruinsma, F., Turner, J., Hertzberg, M., Seymour, J. F., Prince, H. M., Trotman, J., Verner, E., Roncolato, F., Opat, S., Lindeman, R., Tiley, C., Milliken, S. T., Underhill, C. R., Benke, G., Giles, G. G. & Vajdic, C. M., 9 Jan 2024, In: Cancer Epidemiology, Biomarkers and Prevention. 33, 1, p. 106-116 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Citation (Scopus) -
Attitudes towards COVID-19 Vaccination in Adults with Haematological Malignancies
Blennerhassett, R., Hamad, N., Grech, L., Kwok, A., Choi, T., Forsyth, C., Jagger, J., Opat, S., Harris, S., Chan, B. A., Nguyen, M., Bain, N., Day, D., Segelov, E. & on behalf of the CANVACCS Investigators, Sept 2024, In: Acta Haematologica. 147, 5, p. 543-554 12 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access